Back to search
FDAFDA · Food and drugs·Recall number Z-2834-2026

REMISOL Advance with Software Version 2.5 UDI-DI code: 15099590802073 The Normand Info REMISOL Advance Data Manager collects and manages data and workflow for 128 connections

Published August 12, 2026 · Recall initiated: April 29, 2026

Summary

FDA records medical device Class II recall Z-2834-2026, published August 12, 2026 and initiated April 29, 2026. Recalling firm: Beckman Coulter Biomedical GmbH; Status: Ongoing; Reported quantity: 20 systems; Lot: Software Version 2.5 UDI-DI code: 15099590802073. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Due to software issues where does not handle combo assay results. The software may replace the final combo test result with one of the sub-results resulting in incorrect reporting of test outcomes.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Beckman Coulter Biomedical GmbH
Distributor
U.S.: FL, GA, IL, MI, and PA O.U.S.: Belgium, France, Hungary, Poland, Taiwan (Province of China), Tunisia, United Arab Emirates, and United Kingdom of Great Britain and Northern Ireland.
Lot
Software Version 2.5 UDI-DI code: 15099590802073
Risk classification
Class II
Area (FDA)
device
Country
Germany

Related recalls

Questions about this recall

Was REMISOL Advance with Software Version 2.5 UDI-DI code: 15099590802073 The Normand Info REMISOL Advance Data Manager collects and manages data and workflow for 128 connections recalled?

Yes. FDA published recall Z-2834-2026 on August 12, 2026. Reported hazard: Due to software issues where does not handle combo assay results. The software may replace the final combo test result with one of the sub-results resulting in incorrect reporting of test outcomes.

What should I do if I have this product?

Voluntary: Firm initiated · Letter